BriaCell Therapeutics Corp. (BCTX)
| Previous Close | 4.8700 |
| Open | 5.0100 |
| Bid | 4.9100 x 3200 |
| Ask | 5.1000 x 900 |
| Day's Range | 4.7350 - 5.0800 |
| 52 Week Range | 3.1400 - 12.4700 |
| Volume | |
| Avg. Volume | 844,515 |
| Market Cap | 79.564M |
| Beta (5Y Monthly) | 1.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
BriaCell Adds Additional Clinical Sites to Broaden Patient Access and Further Boost Enrollment
PHILADELPHIA and VANCOUVER, British Columbia, May 18, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that it has activated Hoag Memorial Hospital Presbyterian (“Hoag”) and re-engaged Sylvester Comprehensive Cancer Center, part of UHealth – the University of Miami Health System, as two additional clinical sites
- GlobeNewswire
BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy
U.S. Food and Drug Administration (FDA) has granted Fast Track status to BriaCell’s lead candidate, Bria-IMT™, for the treatment of metastatic breast cancer.Fast Track improves the speed and frequency of communication with FDA, potentially leading to earlier drug approval and access by patients.BriaCell is currently enrolling and dosing advanced breast cancer patients in a Phase I/IIa study, now with Fast Track designation. PHILADELPHIA and VANCOUVER, British Columbia, April 13, 2022 (GLOBE NEWS
- GlobeNewswire
BriaCell Presents Development Details of Bria-OTS™ Platform Technology at the American Association for Cancer Research (AACR) Annual Meeting 2022
Based on clinical data with Bria-IMT™, BriaCell has developed Bria-OTS™, an off-the-shelf (i.e. pre-manufactured) personalized immunotherapy.Bria-OTS™ will be used to treat patients with advanced breast cancer, providing patients with readily available personalized treatment. PHILADELPHIA and VANCOUVER, British Columbia, April 12, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializin
